17 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 15 Phase 3, 4 Phase 2, 2 Not applicable, 1 Phase 1, 1 Phase 4.
Follow Vaccines, Synthetic: new trials by email Literature Review of Vaccines, Synthetic trials Research Report on Vaccines, Synthetic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity and Safety of HPV-4 Vaccine With or Without Td Vaccine in Children Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine, Tetanus-Diphtheria booster - Human Papillomavirus (HPV) Infection | Phase 3 | Not yet recruiting | PT Bio Farma | 266 | 2026-10-01 | 2026-09-17 |
| A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha), Placebo - Genital Wart, Penile Cancer | Phase 3 | Active not recruiting | Shanghai Bovax Biotechnology Co., Ltd. | 9000 | 2024-07-11 | 2024-12-12 |
| A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha), Placebo - Cervical Cancer, Genital Wart | Phase 3 | Terminated | Shanghai Bovax Biotechnology Co., Ltd. | 3131 | 2022-12-09 | 2023-07-21 |
| Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine - HPV Infection, HPV Vaccination | Phase 4 | Completed | University of Washington | 158 | 2022-05-25 | 2023-11-29 |
| Gardasil Versus Cervarix in the Treatment of Warts Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine, Bivalent Human Papilloma Virus Vaccine, Saline - Verruca Viral | Phase 3 | Completed | Zagazig University | 50 | 2020-09-01 | 2022-05-20 |
| Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL® - Cervical Cancer, Vulvar Cancer | Phase 3 | Recruiting | Shanghai Bovax Biotechnology Co., Ltd. | 8000 | 2020-04-28 | 2024-06-07 |
| A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213) V501 - Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ | Phase 3 | Completed | Merck Sharp & Dohme LLC | 766 | 2018-08-31 | 2024-12-31 |
| Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study Gardasil® [Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant vaccine], Two dose, Control group - Cancer of Cervix | Phase 2 / Phase 3 | Completed | Instituto Nacional de Salud Publica, Mexico | 6000 | 2018-05-30 | 2021-12-08 |
| Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine - Human Papilloma Virus | Phase 3 | Unknown | Universidad Nacional Autonoma de Mexico | 500 | 2015-02-01 | 2015-03-09 |
| Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds Zostavax, HZ/su vaccine, Placebo - Shingles, Herpes Zoster | Phase 1 | Completed | University of Colorado, Denver | 160 | 2014-05-01 | 2020-07-08 |
| Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58), laboratory biomarker analysis, survey administration - Cancer Survivor, Prevention of Human Papillomavirus Infection | Phase 2 | Completed | University of Alabama at Birmingham | 1499 | 2012-07-01 | 2021-10-27 |
| GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™), Placebo - Papillomavirus Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 250 | 2011-03-21 | 2018-11-14 |
| An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED) Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®), Comparator: Placebo - Papillomavirus Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 600 | 2008-07-20 | 2017-04-17 |
| Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine - Dose Schedule Study | Not applicable | Completed | PATH | 903 | 2007-10-01 | 2017-04-14 |
| A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) V504, Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, Comparator: Placebo (unspecified) - Cervical Cancer, Vulvar Cancer | Phase 2 | Completed | Merck Sharp & Dohme LLC | 620 | 2007-10-01 | 2015-06-08 |
| The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata Saline, Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine - HIV Positive, Anal Condylomata | Not applicable | Completed | Washington University School of Medicine | 32 | 2007-07-01 | 2016-07-25 |
| V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028) Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501), Comparator: Placebo (unspecified) - HPV Infections | Phase 2 | Completed | Merck Sharp & Dohme LLC | 107 | 2006-12-11 | 2017-04-21 |
| An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, Comparator: placebo (unspecified) - Condylomata Acuminata | Phase 3 | Completed | Merck Sharp & Dohme LLC | 4065 | 2004-09-03 | 2018-08-23 |
| Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016) V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine - Cervical Cancer, Genital Warts | Phase 3 | Completed | Merck Sharp & Dohme LLC | 3055 | 2002-12-01 | 2015-01-13 |
| Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED) V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years - Cervical Cancer, Genital Warts | Phase 3 | Completed | Merck Sharp & Dohme LLC | 3882 | 2002-06-28 | 2017-03-22 |
Showing 20 of 22. Sign in to see all of them.
Condylomata Acuminata (10) · Uterine Cervical Neoplasms (10) · Papillomavirus Infections (6) · Vaginal Neoplasms (3) · Vulvar Neoplasms (3) · Anus Neoplasms (1) · HIV Infections (1) · HIV Seropositivity (1) · Herpes Zoster (1) · Infections (1) · Neoplasms (1) · Penile Neoplasms (1) · Uterine Cervical Dysplasia (1)
Merck Sharp & Dohme LLC (10) · Shanghai Bovax Biotechnology Co., Ltd. (3) · Instituto Nacional de Salud Publica, Mexico (1) · PATH (1) · PT Bio Farma (1) · Universidad Nacional Autonoma de Mexico (1) · University of Alabama at Birmingham (1) · University of Colorado, Denver (1) · University of Washington (1) · Washington University School of Medicine (1) · Zagazig University (1)
China (4) · United States (3) · Mexico (2) · Egypt (1) · Indonesia (1) · Kenya (1) · Vietnam (1)
Dominicus Husada, Professor (1) · Kathy Neuzil, MD, MPH (1) · Lidong Gao, Master (1) · Long Sui, Doctor (1) · Myron J Levin, M.D. (1) · Nelly Mugo, MD (1) · Steven R Hunt, MD (1) · Wendy Landier, PhD, CRNP (1)
PMID 32184277, PMID 41276263, PMID 19236277, PMID 19236279, PMID 19935017, PMID 19453788, PMID 19505910, PMID 20949623, PMID 21288094, PMID 21300618, PMID 21307649, PMID 21471141, PMID 21486975, PMID 22029979, PMID 22433961, PMID 22454089, PMID 23066159, PMID 23299013, PMID 23831322, PMID 23901077, PMID 25912475, PMID 28837404, PMID 29029053, PMID 29074187, PMID 29306506, PMID 29995724, PMID 30247596, PMID 30982556, PMID 31291010, PMID 32247041, PMID 32552278, PMID 32827835, PMID 33239228, PMID 34265048, PMID 34767765, PMID 34780705, PMID 34850039, PMID 35149535, PMID 35525430, PMID 38012959, PMID 41162330, PMID 41166720, PMID 41400842
2004 (1), 2023 (1), R01CA166559 (1)